Neurophet (Co-CEOs Bin Jun-gil and Kim Dong-hyun), which develops artificial intelligence (AI) solutions for diagnosing and treating brain diseases, announced on the 29th that it has signed a joint research agreement with global biopharmaceutical company Roche (F. Hoffmann-La Roche Ltd) and is embarking on a full-scale technological collaboration.
This agreement formalizes Neurofit's collaboration with Roche, bringing the ongoing data sharing and technology discussions into a more concrete phase. The scope of the collaboration will include validation of AI model performance using large-scale clinical data and follow-up research and development.
Neurofit explained that this agreement will provide a foundation for national medical device approval and product reliability verification, leveraging the large-scale global clinical data available. Beginning with joint research, the two companies plan to further advance their technology and explore mid- to long-term business collaboration.
Neurofit provides solutions that objectively assess the efficacy of new drugs, such as anti-amyloid antibody treatments, through quantitative analysis techniques utilizing brain magnetic resonance imaging (MRI) and positron emission tomography (PET). This technology is expected to be useful for global pharmaceutical companies in verifying the efficacy of brain disease treatments during clinical trials.
The company views this collaboration with Roche as an opportunity to expand into global markets, and is also considering the possibility of further joint research and business agreements in the future.
Bin Jun-gil, co-CEO of Neurofit, said, “In a domestic environment where it is difficult to secure large-scale medical data, signing a joint research agreement with Roche, a global pharmaceutical company, is a very meaningful step forward.” He added, “Through this collaboration, we aim to advance our technology and ultimately provide solutions that can contribute to the development of therapeutics and clinical trials.”
- See more related articles
You must be logged in to post a comment.